Dr. Feyen oversees all preclinical activities at ThromboGenics. He joined ThromboGenics in October 2013 from Galapagos, where he was the VP for alliance and portfolio management. He started his professional career with an academic appointment at the University of Connecticut Health Center. After that, he held several positions in the pharmaceutical and biotech industries.
Jean progressed through the ranks in several drug discovery positions in Switzerland and the US, finally heading the translational science and disease biology effort on cardiovascular and metabolic disease at Bristol-Myers Squibb.
Jean holds a PhD from the University of Leiden and is an inventor on several patents. He has authored more than sixty peer-reviewed publications. Jean is currently an adjunct professor in the department of pharmacology at the University of Medicine and Dentistry of New Jersey.
MEET JEAN FEYEN AT #KFG2018
Jean Feyen will give a presentation in the session "Future Platforms to DISCOVER":
‘The industry pipeline for diabetic eye disease, what does it hold?’
Chronically high blood sugar from diabetes is associated with damage to the tiny blood vessels in the retina, leading to diabetic retinopathy which causes blood vessels in the retina to leak fluid or hemorrhage (bleed). Diabetic retinopathy can result in distorted vision. In its most advanced stage, new abnormal blood vessels proliferate on the surface of the retina, which can lead to scarring and cell loss in the retina potentially causing severe vision loss and eventually blindness. Anti-VEGF therapy and steroids are the current standard of care. Although efficacious, these therapies still show a clear medical need related to safety and non-responder rates. The presentation will provide an overview of novel treatments being developed in the diabetic retinopathy field.